The impact of SGLT-2 Inhibitors on the Risk of Atrial Fibrillation in Heart Failure.

Background: Heart failure (HF) and atrial fibrillation (AF) are closely linked, each exacerbating the other. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) are known to provide substantial benefits in HF management, their effect on AF incidence in this population is not well-defined.

Objective: This study aims to assess the effect of SGLT2i therapy on the development of new-onset AF in patients with HF.

Use of drug-eluting, balloon-expandable resolute onyx coronary stent as a novel treatment strategy for vertebral artery ostial stenosis: Case series.

Introduction: Vertebral artery (VA) ostial stenosis is notoriously difficult to treat using bare-metal stents owing to high rates of restenosis and stent kinking and breakage. We investigated the safety and effectiveness of treatment with a drug-eluting, balloon-expandable coronary stent (Resolute Onyx, Medtronic).

Methods: Our prospectively maintained database was retrospectively searched for consecutive patients diagnosed with VA ostial stenosis who underwent Resolute Onyx stenting with/without angioplasty between January 1, 2015 and January 1, 2022.